Interview: Chen Qiyu – Chairman, Fosun Pharma, China
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun…
Address: Fosun Commercial Building No. 2 Fuxing Road (East) Shanghai,
Zip Code:200010
,China
Tel: -23137935
Web: http://www.fosunpharma.com/
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196), was established in 1994 and listed on Shanghai Stock Exchange in August 1998. Now it has turned a leading listed company in Chinese pharmaceutical industry.
Fosun Pharma’s net profits have increased by 13.55 times since its 13-year listed and its annual compound growth rate has reached 24.26%. Meanwhile, its net assets and net profits are in front rank of the listed companies in Chinese pharmaceutical industry.
Fosun Pharma specializing in modern biological medical & health industry, has taken great opportunities of the rapid growth of China’s medical market and Chinese enterprises’ access to the world’s predominant medical market, and accelerated industry integration and implemented key product strategy by following the business principle of “Brand, Innovation, High-efficiency and Globalization” so as to realize stable operation and rapid development, at the same time, it has become a large pharmaceutical group on the aspect of R&D, innovation, marketing, merging & integration and team building by regarding R&D, manufacturing and distribution of the medicines as the core and taking the lead of the scale and market role in diagnostic medicines and medical instruments.
Vertically integrated pharmaceutical company
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun…
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to…
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in…
More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that continuously surpasses that of the US and other developed…
Hong Kong is now the world’s second largest funding hub for biotech according to Hong Kong Chief Executive Carrie Lam. During her speech at the 2nd HKEx Biotech Summit on…
On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of Shanghai, China. Following a global re-organization mid-2018, Pfizer now operates three business…
Carsten Lu of Chinese biotech Adlai Nortye outlines his strategy for navigating a crowded immuno-oncology field in China, his partnership strategy, and the firm’s early move to establish a footprint…
Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps…
See our Cookie Privacy Policy Here